5 most recent filings and news items mentioning VTGN. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/VTGN/news?limit=20"
Pull VTGN filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayVistagen Therapeutics, Inc. executed an indemnification agreement with Director Douglas J. Williamson, bolstering protections against executive liability.
View filing at SEC.gov →Vistagen Therapeutics notified investors that its intranasal social anxiety drug failed to meet primary and secondary endpoints in the PALISADE-4 trial. Despite a post-hoc sign of efficacy in severely ill patients, the company is pivoting to a new FDA discussion regarding a poten
View filing at SEC.gov →Vistagen completed the randomized portion of its PALISADE-4 Phase 3 trial evaluating fasedienol for acute social anxiety disorder treatment, with results expected this month. The company also advanced a Phase 2 repeat dose study and received FDA approval to proceed with refisolon
View filing at SEC.gov →Vistagen announced its fasedienol nasal spray program for social anxiety disorder has met international safety database exposure standards with over 1,500 subjects enrolled. The milestone supports the company's path toward potential NDA submission, with Phase 3 PALISADE-4 topline
View filing at SEC.gov →Vistagen Therapeutics executed an indemnification agreement effective May 18, 2026 with Dr. Angel S. Angelov, an officer of the company, to protect him against personal liability and advance legal expenses. The agreement includes standard change-of-control provisions and coverage
View filing at SEC.gov →